Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

Summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors. This is a phase Ib, open-label, multi-center study to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-20093 combination with HRS-5041 in patients with advanced prostate cancer.

Timeline

Start

2025-08-19

Primary completion

2027-12

Completion

2028-12

Drugs

Indications